Insider Buying: Eli Lilly And Co (NYSE:LLY) CFO Buys 426 Shares of Stock

Eli Lilly And Co (NYSE:LLY) CFO Joshua L. Smiley purchased 426 shares of Eli Lilly And Co stock in a transaction that occurred on Wednesday, June 5th. The stock was bought at an average cost of $118.03 per share, with a total value of $50,280.78. Following the completion of the transaction, the chief financial officer now owns 30,410 shares of the company’s stock, valued at $3,589,292.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NYSE LLY traded down $0.68 during trading hours on Friday, hitting $110.79. 6,062,858 shares of the stock were exchanged, compared to its average volume of 10,817,183. The company has a market cap of $108.54 billion, a P/E ratio of 19.96, a price-to-earnings-growth ratio of 1.97 and a beta of 0.27. Eli Lilly And Co has a 12-month low of $84.71 and a 12-month high of $132.13. The stock has a 50-day moving average of $115.50. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.32 by $0.01. The firm had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.31 earnings per share. On average, analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $0.645 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 annualized dividend and a yield of 2.33%. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.

A number of hedge funds and other institutional investors have recently bought and sold shares of LLY. Athena Capital Advisors LLC acquired a new position in Eli Lilly And Co during the fourth quarter worth about $26,000. Wakefield Asset Management LLLP acquired a new position in Eli Lilly And Co during the fourth quarter worth about $27,000. Trust Department MB Financial Bank N A grew its position in Eli Lilly And Co by 54.7% during the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after buying an additional 82 shares during the period. Larson Financial Group LLC acquired a new position in Eli Lilly And Co during the fourth quarter worth about $29,000. Finally, Acima Private Wealth LLC acquired a new position in Eli Lilly And Co during the fourth quarter worth about $33,000. 79.38% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts recently weighed in on LLY shares. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. JPMorgan Chase & Co. started coverage on shares of Eli Lilly And Co in a research report on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 price target for the company. Guggenheim cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price target for the company. in a research report on Thursday, April 11th. Credit Suisse Group set a $121.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Friday, March 22nd. Finally, TheStreet cut shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a report on Thursday, May 9th. Ten investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $119.99.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Market Perform

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.